| Old Articles: <Older 2771-2780 Newer> |
|---|
 |
The Motley Fool
March 16, 2006
Seth Jayson |
PainCare Hurts A big restatement is not made any better by the fact that it's "noncash." Should that matter to investors? You bet.   |
The Motley Fool
March 16, 2006
Rich Duprey |
Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note. |
CFO
March 15, 2006
P.B. Gray |
Rx for Merger Trauma Amid a resurgence in M&A, a veteran offers lessons learned from the difficult merger of Beth Israel Hospital and New England Deaconess Hospital. |
The Motley Fool
March 15, 2006
Stephen D. Simpson |
A Nasty Break for OrthoLogic A trial failure snaps this stock's valuation in half. Biotech investing is hard enough on its own, so don't make it even harder by depending upon risky concepts. |
The Motley Fool
March 14, 2006
Brian Gorman |
AstraZeneca's Heartening News A new study shows cholesterol drug Crestor's further potential. Will it help sales? |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
March 2006
Salamone & Davies |
Merck President Touts Technology Benefits Peter Kim, president of Merck Research Laboratories, says that small changes in the drug discovery and development process can yield significant benefits in bringing new drugs to market. |
Bio-IT World
March 2006
John Russell |
Genzyme's Guerilla Informatics Whether by wisdom or necessity, Genzyme didn't fall prey to industry infatuation with bioinformatics tools. |
Bio-IT World
March 2006 |
Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc. |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
| <Older 2771-2780 Newer> Return to current articles. |
